Development of a Blood-based Diagnostic for Early Detection of Transthyretin Amyloidosis
开发用于早期检测运甲状腺素蛋白淀粉样变性的基于血液的诊断方法
基本信息
- 批准号:10547120
- 负责人:
- 金额:$ 27.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-05 至 2024-08-04
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAlzheimer&aposs DiseaseAmyloidAmyloid depositionAmyloidosisAntibodiesBiological AssayBiological MarkersBiopsyBloodBlood specimenBuffersClinicalClinical TrialsClinical Trials DesignDataDepositionDetectionDevelopmentDiagnosisDiagnosticDiagnostic TrialDiseaseDisease ProgressionDissociationEarly DiagnosisEarly treatmentEnzyme-Linked Immunosorbent AssayFunctional disorderFutureGenesHeartHeart failureHumanImaging TechniquesIndividualInheritedLife ExpectancyMedicalMonitorMonoclonal AntibodiesMutationOutcomePatient CarePatient RecruitmentsPatient-Focused OutcomesPatientsPeripheral NervesPersonsPharmacotherapyPhasePhysiciansPlasmaPlayPolyneuropathyPrealbuminProcessProteinsQuality of lifeRadionuclide ImagingRapid diagnosticsRecombinantsReportingRiskRoleSamplingSeverity of illnessSpecialistSymptomsTechnologyTissuesTreatment EfficacyTreatment ProtocolsWorkaccurate diagnosisbaseblood-based biomarkercommercializationcost effectivedesigndetection limitdiagnostic biomarkerdiagnostic tooldisease diagnosisdisease diagnosticdisorder riskdrug efficacyeffective therapyexperienceextracellularimprovedmonomermortalitynoninvasive diagnosisnovelnovel diagnosticsnovel therapeuticspatient populationrapid diagnosisscreeningsingle moleculesuccess
项目摘要
ABSTRACT
Transthyretin amyloidosis (ATTR) is a rare, progressive, and ultimately fatal condition characterized by the
abnormal extracellular deposition of transthyretin (TTR) protein within the peripheral nerves (ATTR-PN) and/or
within the heart (ATTR-CM). There are two types of ATTR: (1) hereditary ATTR (hATTR), where the destabilizing
mutation in the TTR-gene is inherited, or (2) ATTRwt, in which people with the wild-type TTR-gene sequence
develop the disease sporadically. Recent estimates put the worldwide number of people affected by ATTR at
approximately 550,000. However, these patient populations are thought to be significantly underdiagnosed, as
there is a lack of rapid and readily available diagnostics.
New diagnostics for ATTR disease are needed as confirmation of ATTR is slow, taking up 5 years. Many patients
present with symptoms that can be attributed to other conditions, leading to misdiagnosis. Due to this, ATTR is
often diagnosed by process of elimination of other diseases and many patients have to see multiple specialists
before getting the correct diagnosis, causing a delay in treatment and further amyloid deposition. Given that the
life expectancy once diagnosed with ATTR is only 2-10 years, a blood-based diagnostic and biomarker could be
used to shift the current paradigm from confirmation of late-stage deposition to a clinical level screen, allowing
an individual with suspected risk to receive disease-modifying treatment earlier, reducing mortality, and
improving patient quality of life. Furthermore, a diagnostic biomarker will be invaluable in determining the efficacy
of drugs for treatments which have been shown to have variable long-terms outcomes for patients. This will allow
physicians to guide patients to the most cost effective and appropriate approved drug therapies for their
condition.
The path from normal TTR to amyloid deposition proceeds through a monomeric intermediate which can be a
biomarker of disease risk and progression. The proposed blood-based diagnostic is designed specifically to
detect the TTR monomer using novel, ultra-rare antibodies that have been discovered and will be rapid, sensitive,
and non-invasive. In Phase 1, initial proof-of-concept data will be generated to show that there is elevated TTR
monomers in patients diagnosed with ATTR compared to normal, healthy donors. If successful, this will be the
first step towards the commercialization of the first blood-based diagnostic for the disease.
抽象的
甲状腺素运载蛋白淀粉样变性 (ATTR) 是一种罕见的、进行性的、最终致命的疾病,其特征是
周围神经内运甲状腺素蛋白 (TTR) 蛋白异常细胞外沉积 (ATTR-PN) 和/或
在心脏内(ATTR-CM)。 ATTR 有两种类型:(1) 遗传性 ATTR (hATTR),其中不稳定因素
TTR 基因突变是遗传性的,或 (2) ATTRwt,其中具有野生型 TTR 基因序列的人
该病呈散发性发展。最近的估计表明,全球受 ATTR 影响的人数为
约550,000。然而,这些患者群体被认为诊断严重不足,因为
缺乏快速且容易获得的诊断方法。
由于 ATTR 的确认过程缓慢,需要 5 年时间,因此需要针对 ATTR 疾病的新诊断方法。很多病人
出现可归因于其他情况的症状,导致误诊。因此,ATTR 是
通常通过消除其他疾病的过程来诊断,许多患者必须去看多名专家
在得到正确的诊断之前,导致治疗延迟和进一步的淀粉样蛋白沉积。鉴于
一旦诊断出 ATTR,预期寿命只有 2-10 年,基于血液的诊断和生物标记物可能会
用于将当前范例从后期沉积确认转变为临床水平筛选,从而允许
疑似有风险的个体应尽早接受疾病缓解治疗,降低死亡率,以及
提高患者的生活质量。此外,诊断生物标志物对于确定疗效具有无价的价值。
用于治疗的药物已被证明对患者具有可变的长期结果。这将允许
医生指导患者采用最具成本效益和最合适的经批准的药物治疗
健康)状况。
从正常 TTR 到淀粉样蛋白沉积的路径通过单体中间体进行,该中间体可以是
疾病风险和进展的生物标志物。拟议的基于血液的诊断是专门设计的
使用已发现的新型、超稀有抗体检测 TTR 单体,该抗体将快速、灵敏、
并且非侵入性。在第一阶段,将生成初始概念验证数据以表明 TTR 有所提高
与正常健康供体相比,诊断为 ATTR 的患者的单体。如果成功的话,这将是
迈出了第一个基于血液的疾病诊断商业化的第一步。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARCIN APOSTOL其他文献
MARCIN APOSTOL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARCIN APOSTOL', 18)}}的其他基金
Brain-penetrant chemical disaggregators of tau fibrils as therapeutics for Alzheimer's Disease
tau 原纤维的脑渗透化学分解剂作为阿尔茨海默氏病的治疗方法
- 批准号:
10384228 - 财政年份:2022
- 资助金额:
$ 27.03万 - 项目类别:
Therapeutic Immunodepletion of a Transthyretin Aggregation Intermediate
转甲状腺素蛋白聚集中间体的治疗性免疫耗竭
- 批准号:
10383792 - 财政年份:2022
- 资助金额:
$ 27.03万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 27.03万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 27.03万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 27.03万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 27.03万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 27.03万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 27.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 27.03万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 27.03万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 27.03万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 27.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




